It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: pfishy
a reply to: Hecate666
This part of the study has already established the low level of risk from the variant formula. It is just focused on determining any changes in efficacy with different dose sizes
originally posted by: AaarghZombies
One reason would be verification, if you started talking about bodies piling up knee deep I could check and see if it was true.
Also, if I know you in the real world I shouldn't be talking to you on this thread. It would be an ethics violation.
FYI Link
originally posted by: TheAiIsLying
So out with it. What is it that you do that would make talking to a vaccine trial participant in real life an ethics violation
originally posted by: pfishy
originally posted by: TheAiIsLying
So out with it. What is it that you do that would make talking to a vaccine trial participant in real life an ethics violation
Well, for one thing, working for the manufacturer or a participating study clinic
originally posted by: pfishy
a reply to: TheAiIsLying
I have no financial dependence on the medical or pharmaceutical industries, but I am a firm believer in the overall benefits humanity has seen from vaccines.
SAN FRANCISCO — Moderna Therapeutics, the most highly valued private company in biotech, has run into troubling safety problems with its most ambitious therapy, STAT has learned — and is now banking on a mysterious new technology to keep afloat its brash promise of reinventing modern medicine.
Exactly one year ago, Moderna CEO Stéphane Bancel talked up his company’s “unbelievable” future before a standing-room-only crowd at the annual J.P. Morgan Healthcare Conference here. He promised that Moderna’s treatment for a rare and debilitating disease known as Crigler-Najjar syndrome, developed alongside biotech giant Alexion Pharmaceuticals, would enter human trials in 2016.
It was to be the first therapy using audacious new technology that Bancel promised would yield dozens of drugs in the coming decade.
ADVERTISEMENT
But the Crigler-Najjar treatment has been indefinitely delayed, an Alexion spokeswoman told STAT. It never proved safe enough to test in humans, according to several former Moderna employees and collaborators who worked closely on the project. Unable to press forward with that technology, Moderna has had to focus instead on developing a handful of vaccines, turning to a less lucrative field that might not justify the company’s nearly $5 billion valuation.
The company’s premise: Using custom-built strands of messenger RNA, known as mRNA, it aims to turn the body’s cells into ad hoc drug factories, compelling them to produce the proteins needed to treat a wide variety of diseases.
But mRNA is a tricky technology. Several major pharmaceutical companies have tried and abandoned the idea, struggling to get mRNA into cells without triggering nasty side effects.
Bancel has repeatedly promised that Moderna’s new therapies will change the world, but the company has refused to publish any data on its mRNA vehicles, sparking skepticism from some scientists and a chiding from the editors of Nature.
The indefinite delay on the Crigler-Najjar project signals persistent and troubling safety concerns for any mRNA treatment that needs to be delivered in multiple doses, covering almost everything that isn’t a vaccine, former employees and collaborators said.
originally posted by: AaarghZombies
originally posted by: pfishy
a reply to: AaarghZombies
The particular study is mRNA-1273-P205 (Moderna).
I'm not prohibited from sharing my participant number, but I am hesitant to do so. What is your reason for wanting to know it, if you don't mind me asking?
One reason would be verification, if you started talking about bodies piling up knee deep I could check and see if it was true.
Also, if I know you in the real world I shouldn't be talking to you on this thread. It would be an ethics violation.
FYI Link